What is the amount, lender, and purpose of Starling Oncology's newly secured credit facility?

Starling Oncology, through its subsidiary, has secured a $25 million revolving credit facility from Gemino Healthcare Finance, which provides financial flexibility for working capital and general corporate purposes without diluting equity.

When did the credit facility close, when does it mature, and what was the initial outstanding balance?

The credit facility closed on August 21, 2026, matures on August 20, 2029, and had $4.75 million outstanding as of the closing date.

Starling Oncology Secures $25M Revolving Credit Line

Aug 22, 2026

Starling Oncology secured a $25 million revolving credit facility from Gemino Healthcare Finance for working capital and general corporate purposes. The facility matures in August 2029 with interest tied to Term SOFR plus 3.95%.

Dealroom

2026-04-15

Ecolab Inc Enters $4.75 Billion Unsecured Term Loan Credit Facility

2026-04-29

Ecolab Inc (ECL) Shares Fall 3.9% -- GF Value Says Still Overvalued

2026-05-11

Ecolab Stock Analyst Consensus Points to 27% Upside Potential

2026-05-20

Ecolab Issues $3.5 Billion Senior Bonds

2026-05-28

Ecolab (ECL) Up 2.3% Since Last Earnings Report: Can It Continue?